Table 2.

Cross tabulation of gender, age groups and full vaccine protocol type with reported individual long-term adverse events

	Gender		Age		Vaccine
	Male (n=150)	Female (n=348)	<40 (n=333)	≥40 (n=165)	PB (n=241)	AZ (n=91)	SP (n=158)	AZ & PB (n=8)
Headache	2 (1.3%)	2 (.6%)	4 (1.2%)	0 (.0%)	1 (.4%)	1 (1.1%)	2 (1.3%)	0 (0%)
P value	0.384		0.158		0.797
Myalgia	4 (2.7%)	4 (1.1%)	7 (2.1%)	1 (.6%)	3 (1.2%)	1 (1.1%)	4 (2.5%)	0 (0%)
P value	0.217		0.211		0.746
Dizziness	1 (.7%)	3 (.9%)	3 (.9%)	1 (.6%)	0 (.0%)	0 (.0%)	4 (2.5%)	0 (0%)
P value	0.823		0.729		0.38
Fatigue	12 (8.0%)	20 (5.7%)	21 (6.3%)	11 (6.7%)	11 (4.6%)	5 (5.5%)	15 (9.5%)	1 (12.5%)
P value	0.347		0.877		0.217
Poor concentration	1 (.7%)	2 (.6%)	3 (.9%)	0 (.0%)	1 (.4%)	2 (2.2%)	0 (0%)	0 (0%)
P value	0.903		0.221		0.159
Arthralgia	1 (.7%)	5 (1.4%)	5 (1.5%)	1 (.6%)	2 (.8%)	1 (1.1%)	3 (1.9%)	0 (0%)
P value	0.470		0.389		0.811
Dyspnea/cough	0 (.0%)	2 (.6%)	1 (.3%)	1 (.6%)	2 (.8%)	0 (0%)	0 (0%)	0 (0%)
P value	0.352		0.612		0544
Hair loss	1 (.7%)	2 (.6%)	2 (.6%)	1 (.6%)	3 (1.2%)	0 (0%)	0 (0%)	0 (0%)
P value	0.903		0.994		0.359
Allergy	0 (.0%)	3 (.9%)	2 (.6%)	1 (.6%)	1 (.4%)	0 (0%)	2 (1.3%)	0 (0%)
P value	0.254		0.994		0.610